|
Selexipag (n=290) |
Inhaled Iloprost (n=92) |
Parenteral Treprostinil (n=201) |
Total (n=583) |
Selexipag (n=166) |
Inhaled Iloprost (n=93) |
Parenteral Treprostinil (n=223) |
Total (n=482) |
| Age, years, mean (SD) |
63.8 (14.2) |
63.3 (13.8) |
57.9 (14.6) |
61.72 (14.5) |
50.1 (11.5) |
51.7 (9.8) |
47.7 (11.5) |
49.3 (11.3) |
| Female, n (%) |
213 (73.4) |
66 (71.7) |
155 (77.1) |
434 (74.4) |
131 (78.9) |
68 (73.1) |
166 (74.4) |
365 (75.7) |
| Insurance type, n (%) |
|
|
|
|
|
|
|
|
| Commercial |
181 (62.4) |
39 (42.4) |
80 (39.8) |
300 (51.5) |
166 (100.0) |
93 (100.0) |
223 (100.0) |
482 (100.0) |
| Medicare |
109 (37.6) |
53 (57.6) |
121 (60.2) |
283 (48.5) |
0 |
0 |
0 |
0 |
| US geographic region, n (%) |
| East North Central |
29 (10.0) |
8 (8.7) |
49 (24.4) |
86 (14.8) |
24 (14.5) |
12 (12.9) |
45 (20.2) |
81 (16.8) |
| East South Central |
15 (5.2) |
2 (2.2) |
3 (1.5) |
20 (3.4) |
6 (3.6) |
7 (7.5) |
14 (6.3) |
27 (5.6) |
| Middle Atlantic |
22 (7.6) |
4 (4.3) |
10 (5.0) |
36 (6.2) |
15 (9.0) |
14 (15.1) |
19 (8.5) |
48 (10.0) |
| Mountain |
32 (11.0) |
11 (12.0) |
33 (16.4) |
76 (13.0) |
7 (4.2) |
3 (3.2) |
20 (9.0) |
30 (6.2) |
| New England |
9 (3.1) |
4 (4.3) |
8 (4.0) |
21 (3.6) |
4 (2.4) |
6 (6.5) |
7 (3.1) |
17 (3.5) |
| Pacific |
25 (8.6) |
19 (20.7) |
27 (13.4) |
71 (12.2) |
22 (13.3) |
11 (11.8) |
23 (10.3) |
56 (11.6) |
| South Atlantic |
99 (34.1) |
24 (26.1) |
34 (16.9) |
157 (26.9) |
36 (21.7) |
20 (21.5) |
44 (19.7) |
100 (20.7) |
| West North Central |
18 (6.2) |
10 (10.9) |
13 (6.5) |
41 (7.0) |
5 (3.0) |
3 (3.2) |
10 (4.5) |
18 (3.7) |
| West South Central |
40 (13.8) |
10 (10.9) |
24 (11.9) |
74 (12.7) |
22 (13.3) |
15 (16.1) |
33 (14.8) |
70 (14.5) |
| Unknown |
1 (0.3) |
0 (0.0) |
0 (0.0) |
1 (0.2) |
25 (15.1) |
2 (2.2) |
8 (3.6) |
35 (7.3) |
| CCI score, mean (SD) |
4.1 (3.2) |
3.8761 (2.8) |
4.0 (2.8) |
4.0 (3.0) |
2.6 (2.5) |
2.4(2.1) |
2.9 (2.4) |
2.7 (2.4) |
| Comorbidities, n (%) |
|
|
|
|
|
|
|
|
| CHD |
27 (9.3) |
9 (9.8) |
22 (10.9) |
58 (9.9) |
22 (13.3) |
13 (14.0) |
26 (11.7) |
61 (12.7) |
| CTD |
49 (16.9) |
20 (21.7) |
47 (23.4) |
116 (19.9) |
22 (13.3) |
21 (22.6) |
52 (23.3) |
95 (19.7) |
| Portal hypertension |
16 (5.5) |
6 (6.5) |
22 (10.9) |
44 (7.5) |
13 (7.8) |
2 (2.2) |
20 (9.0) |
35 (7.3) |
| Hypertension |
228 (78.6) |
70 (76.1) |
143 (71.1) |
441 (75.6) |
93 (56.0) |
53 (57.0) |
125 (56.1) |
271 (56.2) |
| Obesity |
84 (29.0) |
21 (22.8) |
58 (28.9) |
163 (28.0) |
47 (28.3) |
10 (10.8) |
44 (19.7) |
101 (21.0) |
| Hyperlipidemia |
156 (53.8) |
34 (37.0) |
87 (43.3) |
277 (47.5) |
48 (28.9) |
27 (29.0) |
51 (22.9) |
126 (26.1) |
| Heart failure |
166 (57.2) |
49 (53.3) |
138 (68.7) |
353 (60.5) |
60 (36.1) |
45 (48.4) |
134 (60.1) |
239 (49.6) |
| Digital ulcer |
0 (0.0) |
1 (1.1) |
1 (0.5) |
2 (0.3) |
0 (0.0) |
1 (1.1) |
6 (2.7) |
7 (1.5) |
| Asthma |
0 (0.0) |
22 (23.9) |
23 (11.4) |
45 (7.7) |
0 (0.0) |
12 (12.9) |
28 (12.6) |
40 (8.3) |
| COPD |
127 (43.8) |
43 (46.7) |
87 (43.3) |
257 (44.1) |
38 (22.9) |
26 (28.0) |
49 (22.0) |
113 (23.4) |
| Diabetes |
110 (37.9) |
41 (44.6) |
58 (28.9) |
209 (35.8) |
44 (26.5) |
23 (24.7) |
50 (22.4) |
117 (24.3) |
| Depression |
45 (15.5) |
11 (12.0) |
44 (21.9) |
100 (17.2) |
17 (10.2) |
9 (9.7) |
36 (16.1) |
62 (12.9) |
| Baseline PAH-specific treatment, n (%) |
ERA + PDE5i
combination |
167 (57.6) |
30 (32.6) |
51 (25.4) |
248 (42.5) |
98 (59.0) |
42 (45.2) |
46 (20.6) |
186 (38.6) |
| ERA monotherapy |
28 (9.7) |
31 (33.7) |
27 (13.4) |
86 (14.8) |
21 (12.7) |
26 (28.0) |
27 (12.1) |
74 (15.4) |
| PDE5i/sGCS monotherapy |
54 (18.6) |
14 (15.2) |
46 (22.9) |
114 (19.6) |
32 (19.3) |
17 (18.3) |
60 (26.9) |
109 (22.6) |
| None |
41 (14.1) |
17 (18.5) |
77 (38.3) |
135 (23.2) |
15 (9.0) |
8 (8.6) |
90 (40.4) |
113 (23.4) |
| Index year, n (%) |
|
|
|
|
|
|
|
|
| 2009 |
0 (0.0) |
23 (25.0) |
21 (10.4) |
44 (7.5) |
0 (0.0) |
25 (26.9) |
25 (11.2) |
50 (10.4) |
| 2010 |
0 (0.0) |
14 (15.2) |
18 (9.0) |
32 (5.5) |
0 (0.0) |
23 (24.7) |
25 (11.2) |
48 (10.0) |
| 2011 |
0 (0.0) |
24 (26.1) |
18 (9.0) |
42 (7.2) |
0 (0.0) |
11 (11.8) |
24 (10.8) |
35 (7.3) |
| 2012 |
0 (0.0) |
5 (5.4) |
16 (8.0) |
21 (3.6) |
0 (0.0) |
12 (12.9) |
39 (17.5) |
51 (10.6) |
| 2013 |
0 (0.0) |
13 (14.1) |
17 (8.5) |
30 (5.1) |
0 (0.0) |
8 (8.6) |
18 (8.1) |
26 (5.4) |
| 2014 |
0 (0.0) |
4 (4.3) |
13 (6.5) |
17 (2.9) |
0 (0.0) |
8 (8.6) |
25 (11.2) |
33 (6.8) |
| 2015 |
0 (0.0) |
5 (5.4) |
15 (7.5) |
20 (3.4) |
0 (0.0) |
4 (4.3) |
18 (8.1) |
22 (4.6) |
| 2016 |
50 (17.2) |
3 (3.3) |
16 (8.0) |
69 (11.8) |
52 (31.3) |
1 (1.1) |
12 (5.4) |
65 (13.5) |
| 2017 |
51 (17.6) |
1 (1.1) |
24 (11.9) |
76 (13.0) |
28 (16.9) |
1 (1.1) |
5 (2.2) |
34 (7.1) |
| 2018 |
63 (21.7) |
0 (0.0) |
17 (8.5) |
80 (13.7) |
29 (17.5) |
0 (0.0) |
15 (6.7) |
44 (9.1) |
| 2019 |
68 (23.4) |
0 (0.0) |
20 (10.0) |
88 (15.1) |
35 (21.1) |
0 (0.0) |
10 (4.5) |
45 (9.3) |
| 2020 |
58 (20.0) |
0 (0.0) |
6 (3.0) |
64 (11.0) |
22 (13.3) |
0 (0.0) |
7 (3.1) |
29 (6.0) |